SCHEMBL8094890

SCHEMBL8094890

Nc1ncnc2c1ncn2C1CC[C@@H](CO)O1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADA P00813 1/20 0.65
MAPK1 P28482 3/20 0.63
ALDH1A1 P00352 2/20 0.63
LMNA P02545 1/20 0.63
ALB P02768 1/20 0.63
PI4KA P42356 3/20 0.57
PI4K2B Q8TCG2 3/20 0.57
PI4K2A Q9BTU6 3/20 0.57
PI4KB Q9UBF8 3/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
TP53 P04637 1/20 0.57
CYP2C9 P11712 1/20 0.57
NFKB1 P19838 1/20 0.57
HSD17B10 Q99714 1/20 0.57
APEX1 P27695 1/20 0.57
BLM P54132 1/20 0.57
ADCY1 Q08828 1/20 0.57
ADORA3 P0DMS8 6/20 0.56
ADORA2A P29274 5/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9197787 1.00 ADA (0.65) ADAMAPK1ALDH1A1LMNAALB
SCHEMBL18572374 1.00 ADA (0.65) ADAMAPK1ALDH1A1LMNAALB
SCHEMBL3541 1.00 ADA (0.65) ADAMAPK1ALDH1A1LMNAALB
SCHEMBL29609293 1.00 ADA (0.65) ADAMAPK1ALDH1A1LMNAALB
SCHEMBL10381269 1.00 ADA (0.65) ADAMAPK1ALDH1A1LMNAALB
SCHEMBL1374909 1.00 ADA (0.65) ADAMAPK1ALDH1A1LMNAALB
SCHEMBL20419221 1.00 ADA (0.65) ADAMAPK1ALDH1A1LMNAALB
Phosphoric Acid SCHEMBL8630949 0.94 MAPK1 (0.60) ADAMAPK1ALDH1A1LMNAALB
Phosphoric Acid SCHEMBL4966781 0.94 MAPK1 (0.60) ADAMAPK1ALDH1A1LMNAALB
Phosphoric Acid SCHEMBL79814 0.94 MAPK1 (0.60) ADAMAPK1ALDH1A1LMNAALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6040297-A A THERAPEUTIC AGENTS TREATING TUMORS AND RETROVIRAL INFECTIONS INCLUDING HIV INFECTIONS BIOSEARCH ITALIA, S.P.A. (IT) 2000-03-21 US claimed
EP-3131914-B1 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS LLC (US) 2023-05-10 EP disclosed
CN-111909231-A 2 ' and/or 5 ' -amino acid ester phosphoramidate 3 ' -deoxyadenosine derivatives as anticancer compounds 努卡那有限公司 2020-11-10 CN disclosed
CN-107207554-B 2 ' and/or 5 ' -amino acid ester phosphoramidate 3 ' -deoxyadenosine derivatives as anticancer compounds 努卡那有限公司 2020-09-11 CN disclosed
US-20200283775-A1 METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA NOVO NORDISK HEALTH CARE AG (CH) 2020-09-10 US disclosed
EP-3505527-A1 CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION Invivogen (FR) 2019-07-03 EP disclosed
US-6040297-A A THERAPEUTIC AGENTS TREATING TUMORS AND RETROVIRAL INFECTIONS INCLUDING HIV INFECTIONS BIOSEARCH ITALIA, S.P.A. (IT) 2000-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283775-A1 METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA LDHA, LDHB, GLS2 ADA 198/4885MAPK1 4635/4885ALDH1A1 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.